VEGFA and renal cell carcinoma: Novel therapies that focus on different downstream products of the von Hippel-Lindau/hypoxia-inducible factor pathway, such as the vascular endothelial growth factor (VEGF), transforming growth factor-α and platelet-derived growth factor-β, have demonstrated benefits in RCC treatment [9, 10].